;PMID: 2913265
;source_file_2916.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:51..131] = [t:51..131]
;2)sentence:[e:133..173] = [t:133..173]
;3)section:[e:177..197] = [t:177..197]
;4)section:[e:201..288] = [t:201..288]
;5)sentence:[e:292..523] = [t:292..523]
;6)sentence:[e:524..707] = [t:524..707]
;7)sentence:[e:708..804] = [t:708..804]
;8)sentence:[e:805..1040] = [t:805..1040]
;9)sentence:[e:1041..1103] = [t:1041..1103]
;10)sentence:[e:1104..1187] = [t:1104..1187]
;11)sentence:[e:1188..1421] = [t:1188..1421]
;12)section:[e:1425..1469] = [t:1425..1469]

;section 0 Span:0..45
;J Pharmacol Exp Ther.  1989 Jan;248(1):111-8.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (.:[20..21] .) (CD:[23..27] 1989)
        (CD:[28..35] Jan;248) (-LRB-:[35..36] -LRB-) (CD:[36..37] 1)
        (-RRB-:[37..38] -RRB-) (::[38..39] :) (CD:[39..43] 111-)
        (CD:[43..45] 8.)))

;sentence 1 Span:51..131
;Spontaneous regeneration of free muscarinic receptor after alkylation by BM
;123.
;[84..103]:gene-protein:"muscarinic receptor"
(SENT
  (NP-HLN
    (NP (JJ:[51..62] Spontaneous) (NN:[63..75] regeneration))
    (PP (IN:[76..78] of)
      (NP (JJ:[79..83] free)
         (JJ:[84..94] muscarinic) (NN:[95..103] receptor)))
    (PP-TMP (IN:[104..109] after)
      (NP (NN:[110..120] alkylation)))
    (PP (IN:[121..123] by)
      (NP (NN:[124..126] BM) (CD:[127..130] 123)))
    (.:[130..131] .)))

;sentence 2 Span:133..173
;I. Recovery in vivo and in cell culture.
(SENT
  (LST (LS:[133..135] I.))
  (NP (NN:[136..144] Recovery)
    (UCP
      (ADJP (FW:[145..147] in) (FW:[148..152] vivo))
      (CC:[153..156] and)
      (PP (IN:[157..159] in)
        (NP (NN:[160..164] cell) (NN:[165..172] culture))))
    (.:[172..173] .)))
;ERROR_Sentence has multiple children (TB Error):[133..173]::LST:NP:

;section 3 Span:177..197
;Waite JJ, Jenden DJ.
(SEC
  (FRAG (NNP:[177..182] Waite) (NNP:[183..185] JJ) (,:[185..186] ,)
        (NNP:[187..193] Jenden) (NNP:[194..197] DJ.)))

;section 4 Span:201..288
;Department of Pharmacology, School of Medicine, University of California, Los
; Angeles.
(SEC
  (FRAG (NNP:[201..211] Department) (IN:[212..214] of)
        (NNP:[215..227] Pharmacology) (,:[227..228] ,) (NNP:[229..235] School)
        (IN:[236..238] of) (NNP:[239..247] Medicine) (,:[247..248] ,)
        (NNP:[249..259] University) (IN:[260..262] of)
        (NNP:[263..273] California) (,:[273..274] ,) (NNP:[275..278] Los)
        (NNP:[280..287] Angeles) (.:[287..288] .)))

;sentence 5 Span:292..523
;The recovery of rat muscarinic receptor number from the effects of a specific
; alkylating ligand, N-[4-(2-chloroethylmethylamino)-2-butynyl]-2-pyrrolidone
;(BM  123), in three tissues is presented as an exponential function of time.
;[312..331]:gene-protein:"muscarinic receptor"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[292..295] The) (NN:[296..304] recovery))
      (PP (IN:[305..307] of)
        (NP
          (NP (NN:[308..311] rat)
            (NML (JJ:[312..322] muscarinic) (NN:[323..331] receptor))
            (NN:[332..338] number))
          (PP (IN:[339..343] from)
            (NP
              (NP (DT:[344..347] the) (NNS:[348..355] effects))
              (PP (IN:[356..358] of)
                (NP
                  (NP (DT:[359..360] a) (JJ:[361..369] specific)
                      (VBG:[371..381] alkylating) (NN:[382..388] ligand))
                  (,:[388..389] ,)
                  (NP
                      (NN:[390..446] N--LSB-4--LRB-2-chloroethylmethylamino-RRB--2-butynyl-RSB--2-pyrrolidone)
                    (PRN (-LRB-:[447..448] -LRB-)
                      (NP (NN:[448..450] BM) (CD:[452..455] 123))
                      (-RRB-:[455..456] -RRB-))))))))))
    (,:[456..457] ,)
    (PP (IN:[458..460] in)
      (NP (CD:[461..466] three) (NNS:[467..474] tissues)))
    (VP (VBZ:[475..477] is)
      (VP (VBN:[478..487] presented)
        (NP-1 (-NONE-:[487..487] *))
        (PP (IN:[488..490] as)
          (NP
            (NP (DT:[491..493] an) (JJ:[494..505] exponential)
                (NN:[506..514] function))
            (PP (IN:[515..517] of)
              (NP (NN:[518..522] time)))))))
    (.:[522..523] .)))

;sentence 6 Span:524..707
;No  significant difference was found in the recovery rate constants derived
;from  analysis of recovery time courses in corpus striatum, cerebral cortex
;and ileal  longitudinal muscle.
(SENT
  (S
    (NP-SBJ-1 (DT:[524..526] No) (JJ:[528..539] significant)
              (NN:[540..550] difference))
    (VP (VBD:[551..554] was)
      (VP (VBN:[555..560] found)
        (NP-1 (-NONE-:[560..560] *))
        (PP (IN:[561..563] in)
          (NP
            (NP (DT:[564..567] the)
              (NML (NN:[568..576] recovery) (NN:[577..581] rate))
              (NNS:[582..591] constants))
            (VP (VBN:[592..599] derived)
              (NP (-NONE-:[599..599] *))
              (PP (IN:[600..604] from)
                (NP
                  (NP (NN:[606..614] analysis))
                  (PP (IN:[615..617] of)
                    (NP
                      (NP
                        (NML (NN:[618..626] recovery) (NN:[627..631] time))
                        (NNS:[632..639] courses))
                      (PP (IN:[640..642] in)
                        (NP
                          (NP (NN:[643..649] corpus) (NN:[650..658] striatum))
                          (,:[658..659] ,)
                          (NP (JJ:[660..668] cerebral) (NN:[669..675] cortex))
                          (CC:[676..679] and)
                          (NP (JJ:[680..685] ileal) (JJ:[687..699] longitudinal)
                              (NN:[700..706] muscle)))))))))))))
    (.:[706..707] .)))

;sentence 7 Span:708..804
;The single rate constant (0.021/hr) was also independent of  amount and
;duration of BM 123 dose.
(SENT
  (S
    (NP-SBJ (DT:[708..711] The) (JJ:[712..718] single) (NN:[719..723] rate)
            (NN:[724..732] constant)
      (PRN (-LRB-:[733..734] -LRB-)
        (NP
          (QP (CD:[734..739] 0.021) (SYM:[739..740] /))
          (NN:[740..742] hr))
        (-RRB-:[742..743] -RRB-)))
    (VP (VBD:[744..747] was) (RB:[748..752] also)
      (ADJP-PRD (JJ:[753..764] independent)
        (PP (IN:[765..767] of)
          (NP
            (NP (NN:[769..775] amount) (CC:[776..779] and)
                (NN:[780..788] duration))
            (PP (IN:[789..791] of)
              (NP (NN:[792..794] BM) (CD:[795..798] 123) (NN:[799..803] dose)))))))
    (.:[803..804] .)))

;sentence 8 Span:805..1040
;Additional analysis of agonist-defined high  and low affinity subsites in
;cortex revealed that recovery of these populations  also followed similar
;time courses although the alkylation proceeds more slowly  for the high
;affinity sites.
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[805..815] Additional) (NN:[816..824] analysis))
      (PP (IN:[825..827] of)
        (NP
          (NP
            (NP
              (ADJP-1 (NN:[828..835] agonist) (HYPH:[835..836] -)
                      (VBN:[836..843] defined))
              (NML (JJ:[844..848] high)
                (NML-2 (-NONE-:[848..848] *P*)))
              (NML-3 (-NONE-:[848..848] *P*)))
            (CC:[850..853] and)
            (NP
              (ADJP-1 (-NONE-:[853..853] *P*))
              (NML (JJ:[854..857] low)
                (NML-2 (NN:[858..866] affinity)))
              (NML-3 (NNS:[867..875] subsites))))
          (PP (IN:[876..878] in)
            (NP (NN:[879..885] cortex))))))
    (VP (VBD:[886..894] revealed)
      (SBAR (IN:[895..899] that)
        (S
          (NP-SBJ
            (NP (NN:[900..908] recovery))
            (PP (IN:[909..911] of)
              (NP (DT:[912..917] these) (NNS:[918..929] populations))))
          (ADVP (RB:[931..935] also))
          (VP (VBD:[936..944] followed)
            (NP (JJ:[945..952] similar) (NN:[953..957] time)
                (NNS:[958..965] courses))
            (SBAR-ADV (IN:[966..974] although)
              (S
                (NP-SBJ (DT:[975..978] the) (NN:[979..989] alkylation))
                (VP (VBZ:[990..998] proceeds)
                  (ADVP-MNR (RBR:[999..1003] more) (RB:[1004..1010] slowly))
                  (PP (IN:[1012..1015] for)
                    (NP (DT:[1016..1019] the)
                      (NML (JJ:[1020..1024] high) (NN:[1025..1033] affinity))
                      (NNS:[1034..1039] sites))))))))))
    (.:[1039..1040] .)))

;sentence 9 Span:1041..1103
;The rate constant for recovery of both subsites was  0.029/hr.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1041..1044] The) (NN:[1045..1049] rate)
          (NN:[1050..1058] constant))
      (PP (IN:[1059..1062] for)
        (NP
          (NP (NN:[1063..1071] recovery))
          (PP (IN:[1072..1074] of)
            (NP (DT:[1075..1079] both) (NNS:[1080..1088] subsites))))))
    (VP (VBD:[1089..1092] was)
      (NP-PRD
        (NP (CD:[1094..1099] 0.029))
        (PP (SYM:[1099..1100] /)
          (NP (NN:[1100..1102] hr)))))
    (.:[1102..1103] .)))

;sentence 10 Span:1104..1187
;Recovery from BM 123 alkylation occurred in NG108-15 neuroblastoma X  glioma
;cells.
;[1157..1170]:malignancy-type:"neuroblastoma"
;[1174..1180]:malignancy-type:"glioma"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1104..1112] Recovery))
      (PP (IN:[1113..1117] from)
        (NP (NN:[1118..1120] BM) (CD:[1121..1124] 123)
            (NN:[1125..1135] alkylation))))
    (VP (VBD:[1136..1144] occurred)
      (PP-LOC (IN:[1145..1147] in)
        (NP
          (NML (NN:[1148..1156] NG108-15) (NN:[1157..1170] neuroblastoma)
               (SYM:[1171..1172] X))
          (NN:[1174..1180] glioma) (NNS:[1181..1186] cells))))
    (.:[1186..1187] .)))

;sentence 11 Span:1188..1421
;The presence of cycloheximide in the recovery medium did not  significantly
;inhibit this recovery process in the clonal cell line, suggesting  that de
;novo receptor synthesis is unnecessary for regeneration of unalkylated 
;receptors.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1188..1191] The) (NN:[1192..1200] presence))
      (PP (IN:[1201..1203] of)
        (NP (NN:[1204..1217] cycloheximide)))
      (PP (IN:[1218..1220] in)
        (NP (DT:[1221..1224] the) (NN:[1225..1233] recovery)
            (NN:[1234..1240] medium))))
    (VP (VBD:[1241..1244] did) (RB:[1245..1248] not)
      (ADVP (RB:[1250..1263] significantly))
      (VP (VB:[1264..1271] inhibit)
        (NP (DT:[1272..1276] this) (NN:[1277..1285] recovery)
            (NN:[1286..1293] process))
        (PP (IN:[1294..1296] in)
          (NP (DT:[1297..1300] the) (JJ:[1301..1307] clonal)
              (NN:[1308..1312] cell) (NN:[1313..1317] line)))
        (,:[1317..1318] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1318..1318] *))
          (VP (VBG:[1319..1329] suggesting)
            (SBAR (IN:[1331..1335] that)
              (S
                (NP-SBJ
                  (ADJP (FW:[1336..1338] de) (FW:[1339..1343] novo))
                  (NN:[1344..1352] receptor) (NN:[1353..1362] synthesis))
                (VP (VBZ:[1363..1365] is)
                  (ADJP-PRD (JJ:[1366..1377] unnecessary)
                    (PP (IN:[1378..1381] for)
                      (NP
                        (NP (NN:[1382..1394] regeneration))
                        (PP (IN:[1395..1397] of)
                          (NP (JJ:[1398..1409] unalkylated)
                              (NNS:[1411..1420] receptors)))))))))))))
    (.:[1420..1421] .)))

;section 12 Span:1425..1469
;PMID: 2913265 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1425..1429] PMID) (::[1429..1430] :) (CD:[1431..1438] 2913265)
        (NN:[1439..1440] -LSB-) (NNP:[1440..1446] PubMed) (::[1447..1448] -)
        (NN:[1449..1456] indexed) (IN:[1457..1460] for)
        (NNP:[1461..1469] MEDLINE-RSB-)))
